11th Annual School of Breast Oncology®
11th Annual School of Breast Oncology®
Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology®
was developed. This curriculum-based program focuses exclusively on breast cancer clinical management. The intensive 4-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention and treatment. The curriculum will be evidence based summarizing the existing data for each topic and applying these data to patient cases.
This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.
Disclosure Policy and Conflict of Interest (COI)
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Faculty and Staff Disclosure
The following individuals have no relevant financial relationships with commercial interests to disclose:
Douglas Arthur, MD; Anees B. Chagpar MD, MSc, MA, MPH, FRCS(C), FACS; Elena Elkin, PhD; David Euhus, MD, FACS; Carol Fabian, MD; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH, MSc (EBHC), FRCPC
; Dawn L. Hershman, MD, MS; Syed Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne McTiernan, MD, PhD; Anne Moore, MD; Pamela N. Munster, MD; Soonmyung Paik, MD; Lori J. Pierce, MD, FASTRO; Edward Romond, MD; David M. Schuster, MD; Paul Sperduto, MD, MPP; Jeffrey N. Weitzel, MD
The staff of Physicians' Education Resource®, LLC: Kate Doherty; Ann C. Lichti, CCMEP; Susan Peck, PhD; Emily Valko.
The following individuals have relevant financial relationships with commercial interests to disclose:
Rowan T. Chlebowski, MD, PhD—
Grant/Research Support: Amgen; Consultant: Amgen, Pfizer Inc, Novartis Pharmaceuticals Corporation, Astra-Zeneca; Speaker’s Bureau: Novartis Pharmaceuticals Corporation, Astra-Zeneca; Melody Cobleigh, MD—
Grant/Research Support: Genentech; Charles Loprinzi, MD—
Grant/Research Support: Pfizer Inc; Consultant: Helsinn Therapeutics Inc; Terry Mamounas, MD, MPH, FACS—
Consultant: Genomic Health Inc, Celgene Corporation, Eisai Inc, GE Healthcare; Speaker’s Bureau: Genomic Health Inc; Ruth O’Regan, MD—
Grant/Research Support: Novartis, Genentech; Consultant: Novartis; Joyce O’Shaughnessy, MD—
Advisory Board: Genentech Inc; Consultant: Arno Therapeutics Inc, Eisai Inc, Genentech Inc, GlaxoSmithKline, Johnson & Johnson, Sanofi-Aventis US, Novartis Pharmaceuticals, Pfizer, Celgene Corporation, Corcept Therapeutics, Med Fusion, LLC; Elizabeth Rafferty, MD—
Grant/Research Support: research grant Hologic, Inc, for the investigation of breast tomosynthesis; Hope Rugo, MD—
Grant/Research Support: Genentech/Roche, Novartis, GlaxoSmithKline, Merck, Pfizer, Plexxikon, Amgen, OBI; Speaker’s Bureau: Genomic Health; Hani Sbitany, MD—
Speaker’s Bureau: LifeCell Corporation; Lawrence Solin, MD, FACR, FASTR—
Other Support: (not paid) member of Advisory Board at GHI Pharma; Joseph Sparano, MD—
Grant/Research Support: Merck & Co, Inc, Novartis Pharmaceuticals Corporation; Consultant: Genentech, Eisai Inc, Curis Inc, Novartis Pharmaceuticals Corporation; Alison Stopeck, MD—
Grant/Research Support: Amgen Inc, Peregrine Pharmaceuticals, Inc; Consultant: Pfizer Inc , Amgen Inc, Bayer Corporation, NanoString Technologies; Speaker’s Bureau: Genomic Health; Other Support: (Honoraria) Genentech, GlaxoSmithKline
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.